loratadine galpharm 10mg tablets
galpharm healthcare limited wrafton, braunton, north devon, ex33 2dl, united kingdom - loratadine - tablet - loratadine 10 milligram(s) - antihistamines for systemic use
loratadine chefaro 10mg tablets
chefaro ireland dac the sharp building, hogan place, dublin 2,, ireland - tablet - loratadine 10 mg - antihistamines for systemic use
galpharm non-drowsy hayfever and allergy relief 10mg tablets
galpharm international ltd - loratadine - tablet - 10mg
galpharm non-drowsy allergy relief 10mg tablets
galpharm international ltd - loratadine - tablet - 10mg
galpharm one-a-day allergy and hayfever relief tablets 10mg
cherubino limited - loratadine - tablet - loratadine 10 milligram(s) - antihistamines for systemic use
boots one a day allergy relief 10mg tablets
the boots company plc - loratadine - oral tablet - 10mg
numark one-a-day allergy tablets 10mg
galpharm healthcare limited - loratadine - tablet - loratadine 10 mg - nasal preparations
desloratadine- desloratadine tablet
avpak - desloratadine (unii: fvf865388r) (desloratadine - unii:fvf865388r) - desloratadine 5 mg - desloratadine tablets are indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 12 years of age and older. desloratadine tablets are indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 12 years of age and older. desloratadine tablets are indicated for the symptomatic relief of pruritus, reduction in the number of hives, and size of hives, in patients with chronic idiopathic urticaria 12 years of age and older. - desloratadine tablets are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients or to loratadine [see warnings and precautions ( 5.1) and adverse reactions ( 6.2)]. desloratadine tablets are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients or to loratadine [see warnings and precautions ( 5.1) and adverse reactions ( 6.2)]. pregnancy category c: there are no adequate and well-controlled studies in pregnant
desloratadine tablet
avkare - desloratadine (unii: fvf865388r) (desloratadine - unii:fvf865388r) - desloratadine 5 mg - desloratadine tablets are indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 12 years of age and older. desloratadine tablets are indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 12 years of age and older. desloratadine tablets are indicated for the symptomatic relief of pruritus, reduction in the number of hives, and size of hives, in patients with chronic idiopathic urticaria 12 years of age and older. - desloratadine tablets are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients or to loratadine [see warnings and precautions ( 5.1) and adverse reactions ( 6.2)]. desloratadine tablets are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients or to loratadine [see warnings and precautions ( 5.1) and
desloratadine tablet, orally disintegrating
dr. reddy's laboratories limited - desloratadine (unii: fvf865388r) (desloratadine - unii:fvf865388r) - desloratadine 2.5 mg - desloratadine orally disintegrating tablets are indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 2 years of age and older. desloratadine orally disintegrating tablets are indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 6 months of age and older. desloratadine orally disintegrating tablets are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients or to loratadine [see warnings and precautions (5.1) and adverse reactions (6.2) ] risk summary the limited available data with desloratadine in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. there are no adequate and well-controlled studies in pregnant women. desloratadine given during organogenesis to pregnant rats was not teratogenic at the summed area under the concentration-time curve (auc)-based exposures of desloratadine and its metabo